Pampa Metals Announces Acceleration of Warrant Expiry Date

Pampa Metals Announces Acceleration of Warrant Expiry Date

Pampa Metals Corp. ("PMC" or the "Company") (CSE:PM)(FSE:FIR)(OTCQB:PMMCF) announces the acceleration of the expiry dates of certain share purchase warrants issued on November 10, 2022 (the "2022 Warrants") and March 2, 2023 (the "2023 Warrants"), and amended to reduce the exercise price to $0.095 and $0.105 in September and October of 2023 respectively (see news releases dated September 22, 2023 and October 23, 2023

In accordance with the policies of the Canadian Stock Exchange ("CSE") the expiry date of the warrants is accelerated if the Company's common shares close at or above $0.125 in the case of the 2022 Warrants and $0.13 in the case of the 2023 Warrants, for a period of at least 10 consecutive trading days in each case. This condition was met on December 14, 2023.

As a result, the expiry date of the 2022 Warrants and the 2023 Warrants outstanding (totaling 4,653,140) has been accelerated to January 23, 2024. To date, an aggregate of 2,913,186 of the 2022 Warrants and 2023 Warrants have been exercised for gross proceeds of approximately $295,000.

In order to exercise the warrants, holders of the 2022 Warrants and 2023 Warrants must complete and submit a Notice of Exercise in the form attached to your warrant certificate on or before 4pm Vancouver time on January 23, 2024. Unexercised 2022 Warrants and 2023 Warrants will expire after that time.

ON BEHALF OF THE BOARD
Joseph van den Elsen | President & CEO

INVESTORS CONTACT
Joseph van den Elsen | President & CEO
Joseph@pampametals.com
+1 604 347 8777

ABOUT Pampa Metals

Pampa Metals is listed on the Canadian Stock Exchange (CSE:PM), Frankfurt (FSE: FIR), and OTC (OTCQB: PMMCF) exchanges, and wholly owns a portfolio of projects highly prospective for copper, molybdenum, and gold along proven and highly productive mineral belts in Chile, the world's largest copper producer.

In November 2023, the Company announced it had entered into an Option & JV Agreement for the acquisition of an 80% interest in the Piuquenes Copper-Gold Porphyry Project in San Juan Province, Argentina.

Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

SOURCE:Pampa Metals Corp.



View the original press release on accesswire.com

News Provided by ACCESSWIRE via QuoteMedia

PM:CC
The Conversation (0)
Pampa Metals Intersects 304m at 1.07% CuEq* incl. 132m at 1.45% CuEq* from First Drillhole at the Piuquenes Porphyry Project, Argentina

Pampa Metals Intersects 304m at 1.07% CuEq* incl. 132m at 1.45% CuEq* from First Drillhole at the Piuquenes Porphyry Project, Argentina

Pampa Metals Corp. ("Pampa Metals" or the "Company") (CSE:PM)(FSE:FIR)(OTCQB:PMMCF) is pleased to report assay results for the upper 502 meters of diamond drillhole PIU-01 (refer figure 1) which was recently completed to a depth of 867m at the Company's Piuquenes Central porphyry target located in San Juan Province, Argentina. Assay results for the upper 502m section of hole PIU-01 include

  • 304m @ 0.48% Cu, 0.68 g/t Au, 3.1 g/t Ag (1.07% CuEq)* (from 198 m);
    • including 132 m @ 0.71% Cu, 0.85 g/ Au, 4.3 g/t Ag (1.45% CuEq)* (from 220m); and
    • including 34 m @ 0.60% Cu, 0.93 g/t Au, 3.6 g/t Ag (1.38% CuEq)* (from 468m).

Assays results from 502m to 867m (End Of Hole) are expected shortly.

Keep reading...Show less
Pampa Metals Intersects Wide Interval of Copper Mineralization at Piuquenes, Argentina

Pampa Metals Intersects Wide Interval of Copper Mineralization at Piuquenes, Argentina

Pampa Metals Corp. ("Pampa Metals" or the "Company") (CSE:PM)(FSE:FIR)(OTCQB:PMMCF) is pleased to report that diamond drillhole PIU-01 (refer figure 1) was completed at a downhole depth of 867m. First assay results are expected shortly. Drillhole PIU 02, the second hole of the current program, has commenced

Hole PIU-01, designed to extend Cu-Au mineralization to depth on the southwestern margin of the Piuquenes Central porphyry, intersected a 160m zone of supergene copper enrichment between 220m and 380m downhole, coincident, and overlapping with primary mineralization from 350 meters. Strong primary mineralization associated with intense porphyry A type quartz stockwork veining is evident from 350m to approximately 650m. From 650m to the end of hole at 867m quartz veining and mineralization continues, becoming progressively less intense with depth. From 830m disseminated hematite/specularite-pyrite-chalcopyrite mineralization is hosted in volcanic host rocks outside the porphyry intrusive and remains open at depth.

Keep reading...Show less
Pampa Metals Intersects Thick Supergene Copper Enrichment Blanket and Extends Primary Cu-Au Mineralization to Depth at Piuquenes, San Juan Province, Argentina

Pampa Metals Intersects Thick Supergene Copper Enrichment Blanket and Extends Primary Cu-Au Mineralization to Depth at Piuquenes, San Juan Province, Argentina

Pampa Metals" or the "Company") (CSE:PM)(FSE:FIR)(OTCQB:PMMCF) is pleased to report that drilling to test for lateral and depth extensions below previous high grade porphyry copper-gold intersections at the Piuquenes Cu-Au porphyry project has successfully intersected wide intervals of both secondary and primary mineralization. Excellent progress is being made and drilling is continuing

Diamond drillhole PIU-01 (refer figure 1), designed to extend Cu-Au mineralization to depth on the southwestern margin of the Piuquenes Central porphyry, intersected a 160m thick zone of supergene copper enrichment between 220m to 380m downhole, coincident and overlapping with primary mineralization from 350 meters. PIU-01 has been plotted to approximately 900 meters downhole depth, with primary mineralization continuing from 350m to the current hole depth of approximately 600m.

Keep reading...Show less
Pampa Metals Announces Warrant Exercise

Pampa Metals Announces Warrant Exercise

Pampa Metals Corp. ("Pampa Metals" or the "Company") (CSE:PM)(FSE:FIR)(OTCQB:PMMCF) is pleased to advise that a total of 7,105,586 share purchase warrants issued on November 10, 2022 (the "2022 Warrants") and March 2, 2023 (the "2023 Warrants"), have been exercised, realizing gross proceeds of $729,741.2022 and 2023 Warrants

The exercise price of 1,708,588 2022 Warrants and 5,857,734 2023 Warrants (7,566,322 total) was reduced to $0.095 and $0.105 in September and October of 2023 respectively (see news releases dated September 22, 2023 and October 23, 2023) and, in accordance with the policies of the Canadian Stock Exchange ("CSE"), the expiry date accelerated upon the Company's common shares closing at or above $0.125 in the case of the 2022 Warrants and $0.13 in the case of the 2023 Warrants, for a period of at least 10 consecutive trading days. This condition was met on December 14, 2023, and as a result, the expiry date of the 2022 Warrants and the 2023 Warrants outstanding was accelerated to January 23, 2024.

Keep reading...Show less
Pampa Metals Commences Diamond Drill Program at the Piuquenes Copper-Gold Porphyry Project

Pampa Metals Commences Diamond Drill Program at the Piuquenes Copper-Gold Porphyry Project

Pampa Metals Corp. ("Pampa Metals" or the "Company") (CSE:PM)(FSE:FIRA)(OTCQX:PMMCF) is pleased to advise that follow-up diamond drill testing at the Piuquenes Copper-Gold Porphyry project has commenced. The primary objectives of the program are to test the depth and lateral extension of the high-grade intervals of open mineralization at Piuquenes Central, and its potential to host an orebody of 1,000 m depth and 300 - 500 m diameter

Follow-Up Diamond Drill Program

Keep reading...Show less
Trident Royalties PLC Announces Recommended Cash Offer for Trident by Deterra

Trident Royalties PLC Announces Recommended Cash Offer for Trident by Deterra

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces that it proposes to undertake an up to $4,500,000 non-brokered private placement of flow-through shares (the "Charity FT Shares") to be sold to charitable purchasers at a price of $0.30 per Charity FT Share. The gross proceeds received from the sale of the Charity FT Shares will be used for work programs on the Company's exploration properties. All securities issued and sold under this financing will be subject to a four-month-and-one-day hold period under securities laws in Canada. The Company expects to complete this Charity FT Share financing on or before June 24, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

(TheNewswire)

Heritage Mining Ltd.

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

(TheNewswire)

Noble Mineral Exploration Inc.

Toronto, Ontario TheNewswire - June 11, 2024 Noble Mineral Exploration Inc. ( "Noble" or the "Company" ) (TSX-V:NOB, FRANKFURT: NB7, OTCQB:NLPXF) is pleased to provide the following updates:

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
End of the BAPE Public Information Period 

End of the BAPE Public Information Period 

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") would like to thank all those who participated and enriched the discussions during the public information period of the Bureau d'audiences publiques sur l'environnement (BAPE) and reiterates its commitment to working closely with the community, environmental groups, and authorities for the success of Falco's Horne 5 Project (" Falco's Horne 5 Project " or the " Project" ).

This information period, which was held from April 24 to June 10, 2024, allowed citizens, groups, the municipality and organizations to learn about the various environmental, economic and social aspects of the Project. During this period, it was also possible to make requests for public consultation or mediation to the Minister of the Environment, the Fight against Climate Change, Wildlife and Parks.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024 at 11:20am ET . Management will also host one-on-one investor meetings. Please find additional details about the event below.

Relmada Therapeutics Corporate Logo (PRNewsFoto/Relmada Therapeutics, Inc.)

2024 Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Presentation Date: Wednesday, June 12, 2024 , 11:20am ET
Webcast: Click Here

Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Goldman Sachs representative to schedule a meeting.

The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors . An archived replay will be available for 90 days following the conclusion of the event.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD).  Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302167986.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×